Details of the Drug

General Information of Drug (ID: DMU1GX0)

Drug Name
Mitotane
Synonyms
Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
Indication
Disease Entry ICD 11 Status REF
Adrenocortical carcinoma 2D11.Z Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 320
Logarithm of the Partition Coefficient (xlogp) 6.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 0
ADMET Property
Absorption
The oral absorption of drug is 40% []
Half-life
The concentration or amount of drug in body reduced by one-half in 18 - 159 days [2]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C14H10Cl4
IUPAC Name
1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
Canonical SMILES
C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
InChI
InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
InChIKey
JWBOIMRXGHLCPP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4211
ChEBI ID
CHEBI:6954
CAS Number
53-19-0
DrugBank ID
DB00648
TTD ID
D0Z5OE
ACDINA ID
D00441
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Binder [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1) OTNAZVKB 3BHS1_HUMAN Gene/Protein Processing [4]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2) OT02MSKN 3BHS2_HUMAN Gene/Protein Processing [5]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Protein Interaction/Cellular Processes [6]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [7]
cAMP-dependent protein kinase type I-alpha regulatory subunit (PRKAR1A) OT589JA2 KAP0_HUMAN Gene/Protein Processing [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [8]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [8]
Cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) OT2NV3AN CP11A_HUMAN Gene/Protein Processing [9]
Corticosteroid-binding globulin (SERPINA6) OTOIBEW7 CBG_HUMAN Gene/Protein Processing [10]
CREB-binding protein (CREBBP) OTPA4QGM CBP_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mitotane (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased metabolism of Mitotane caused by Remdesivir mediated induction of CYP450 enzyme. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [12]
Repaglinide DM5SXUV Moderate Increased metabolism of Mitotane caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [13]
Ivosidenib DM8S6T7 Major Increased metabolism of Mitotane caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Midostaurin DMI6E0R Major Increased metabolism of Mitotane caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Moderate Increased metabolism of Mitotane caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Donepezil DMIYG7Z Moderate Increased metabolism of Mitotane caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [17]
Ivabradine DM0L594 Major Increased metabolism of Mitotane caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [12]
Bepridil DM0RKS4 Major Increased metabolism of Mitotane caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [18]
Dronedarone DMA8FS5 Moderate Increased metabolism of Mitotane caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [19]
Nifedipine DMSVOZT Major Increased metabolism of Mitotane caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Major Increased metabolism of Mitotane caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [12]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Mitotane caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [20]
Roflumilast DMPGHY8 Moderate Increased metabolism of Mitotane caused by Roflumilast mediated induction of CYP450 enzyme. Asthma [CA23] [21]
Telithromycin DMZ4P3A Major Increased metabolism of Mitotane caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [12]
Cariprazine DMJYDVK Moderate Increased metabolism of Mitotane caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [22]
Erdafitinib DMI782S Major Increased metabolism of Mitotane caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [23]
Pexidartinib DMS2J0Z Major Decreased metabolism of Mitotane caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [24]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Mitotane caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
HKI-272 DM6QOVN Major Increased metabolism of Mitotane caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
LY2835219 DM93VBZ Major Increased metabolism of Mitotane caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Exemestane DM9HPW3 Moderate Increased metabolism of Mitotane caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Mitotane caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Tucatinib DMBESUA Major Increased metabolism of Mitotane caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [30]
Palbociclib DMD7L94 Major Increased metabolism of Mitotane caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Alpelisib DMEXMYK Major Increased metabolism of Mitotane caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Mitotane caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Mitotane caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Mitotane caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Major Increased metabolism of Mitotane caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [34]
Estradiol DMUNTE3 Moderate Increased metabolism of Mitotane caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Atorvastatin DMF28YC Moderate Increased metabolism of Mitotane caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [35]
Macitentan DMP79A1 Major Increased metabolism of Mitotane caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [36]
PF-04449913 DMSB068 Major Increased metabolism of Mitotane caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [37]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Mitotane caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [38]
Anisindione DM2C48U Moderate Increased metabolism of Mitotane caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [39]
Regorafenib DMHSY1I Moderate Increased metabolism of Mitotane caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [40]
Irinotecan DMP6SC2 Major Increased metabolism of Mitotane caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [41]
Intedanib DMSTA36 Major Increased metabolism of Mitotane caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [42]
Drospirenone DM1A9W3 Moderate Increased metabolism of Mitotane caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [29]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Mitotane caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [29]
Levobupivacaine DM783CH Minor Increased metabolism of Mitotane caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [43]
Alfentanil DMVO0UB Moderate Increased metabolism of Mitotane caused by Alfentanil mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [44]
Osilodrostat DMIJC9X Major Increased metabolism of Mitotane caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [12]
Ivacaftor DMZC1HS Major Increased metabolism of Mitotane caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [26]
Rivaroxaban DMQMBZ1 Major Increased metabolism of Mitotane caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [45]
Aprepitant DM053KT Moderate Increased metabolism of Mitotane caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [46]
Vilazodone DM4LECQ Moderate Increased metabolism of Mitotane caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [47]
Vortioxetine DM6F1PU Moderate Increased metabolism of Mitotane caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [48]
OPC-34712 DMHG57U Moderate Increased metabolism of Mitotane caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [49]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Mitotane caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [26]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Mitotane caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [50]
Ospemifene DMC4GEI Moderate Increased metabolism of Mitotane caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [51]
Ingrezza DMVPLNC Major Increased metabolism of Mitotane caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [52]
Zonisamide DM0DTF7 Moderate Increased metabolism of Mitotane caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [53]
Primidone DM0WX6I Minor Increased metabolism of Mitotane caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Felbamate DM1V5ZS Moderate Increased metabolism of Mitotane caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Fosphenytoin DMOX3LB Minor Increased metabolism of Mitotane caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Ethotoin DMXWOCP Minor Increased metabolism of Mitotane caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Phenobarbital DMXZOCG Minor Increased metabolism of Mitotane caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Cannabidiol DM0659E Moderate Increased metabolism of Mitotane caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [12]
Praziquantel DMOU1PK Major Increased metabolism of Mitotane caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [55]
Bay 80-6946 DMLOS5R Major Increased metabolism of Mitotane caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [56]
Tazemetostat DMWP1BH Major Increased metabolism of Mitotane caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [57]
Mirabegron DMS1GYT Minor Increased metabolism of Mitotane caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [58]
Ripretinib DM958QB Major Increased metabolism of Mitotane caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [59]
Sunitinib DMCBJSR Major Increased metabolism of Mitotane caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [26]
Avapritinib DMK2GZX Major Increased metabolism of Mitotane caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [12]
Ergotamine DMKR3C5 Moderate Increased metabolism of Mitotane caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [26]
Eplerenone DMF0NQR Minor Increased metabolism of Mitotane caused by Eplerenone mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [60]
Boceprevir DMBSHMF Major Increased metabolism of Mitotane caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [61]
Simeprevir DMLUA9D Major Increased metabolism of Mitotane caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [62]
Daclatasvir DMSFK9V Major Increased metabolism of Mitotane caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [12]
Pretomanid DMDYA31 Major Increased metabolism of Mitotane caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [63]
MK-1439 DM215WE Major Increased metabolism of Mitotane caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Delavirdine DM3NF5G Major Increased metabolism of Mitotane caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Mitotane caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Fostemsavir DM50ILT Major Increased metabolism of Mitotane caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Cobicistat DM6L4H2 Major Increased metabolism of Mitotane caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Tipranavir DM8HJX6 Moderate Increased metabolism of Mitotane caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Saquinavir DMG814N Moderate Increased metabolism of Mitotane caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Elvitegravir DMG9B1U Major Increased metabolism of Mitotane caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Etravirine DMGV8QU Major Increased metabolism of Mitotane caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Rilpivirine DMJ0QOW Major Increased metabolism of Mitotane caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Amprenavir DMLMXE0 Moderate Increased metabolism of Mitotane caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Darunavir DMN3GCH Moderate Increased metabolism of Mitotane caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Atazanavir DMSYRBX Moderate Increased metabolism of Mitotane caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Maraviroc DMTL94F Major Increased metabolism of Mitotane caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Levamlodipine DM92S6N Major Increased metabolism of Mitotane caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [18]
Felodipine DMOSW35 Major Increased metabolism of Mitotane caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [18]
Tolvaptan DMIWFRL Major Increased metabolism of Mitotane caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [12]
TP-434 DM5A31S Major Increased metabolism of Mitotane caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [71]
Suvorexant DM0E6S3 Major Increased metabolism of Mitotane caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [72]
Amobarbital DM0GQ8N Minor Increased metabolism of Mitotane caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [20]
Ramelteon DM7IW9J Moderate Increased metabolism of Mitotane caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [73]
Tasimelteon DMLOQ1V Major Increased metabolism of Mitotane caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
ITI-007 DMUQ1DO Major Increased metabolism of Mitotane caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [75]
Pemigatinib DM819JF Major Increased metabolism of Mitotane caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [12]
Crizotinib DM4F29C Major Increased metabolism of Mitotane caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [26]
Brigatinib DM7W94S Major Increased metabolism of Mitotane caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Ceritinib DMB920Z Major Increased metabolism of Mitotane caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [77]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Mitotane caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [78]
PF-06463922 DMKM7EW Major Increased metabolism of Mitotane caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [79]
Osimertinib DMRJLAT Major Increased metabolism of Mitotane caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [26]
Pralsetinib DMWU0I2 Major Increased metabolism of Mitotane caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [80]
Capmatinib DMYCXKL Major Increased metabolism of Mitotane caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [81]
Selpercatinib DMZR15V Major Increased metabolism of Mitotane caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [12]
Artemether DM48QOT Major Increased metabolism of Mitotane caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [26]
Hydroxychloroquine DMSIVND Moderate Increased metabolism of Mitotane caused by Hydroxychloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [26]
Idelalisib DM602WT Major Increased metabolism of Mitotane caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [82]
GDC-0199 DMH0QKA Major Increased metabolism of Mitotane caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [83]
IPI-145 DMWA24P Major Increased metabolism of Mitotane caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
Acalabrutinib DM7GCVW Major Increased metabolism of Mitotane caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [85]
Ibrutinib DMHZCPO Major Increased metabolism of Mitotane caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [12]
Vemurafenib DM62UG5 Major Increased metabolism of Mitotane caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [26]
Selumetinib DMC7W6R Major Increased metabolism of Mitotane caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [86]
LGX818 DMNQXV8 Major Increased metabolism of Mitotane caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [87]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Mitotane caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [26]
Estrone DM5T6US Moderate Increased metabolism of Mitotane caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [29]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Mitotane caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [50]
Ubrogepant DM749I3 Major Increased metabolism of Mitotane caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [88]
Rimegepant DMHOAUG Major Increased metabolism of Mitotane caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [89]
Panobinostat DM58WKG Major Increased metabolism of Mitotane caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [90]
Deflazacort DMV0RNS Major Increased metabolism of Mitotane caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [12]
Romidepsin DMT5GNL Moderate Increased metabolism of Mitotane caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [91]
Fedratinib DM4ZBK6 Major Increased metabolism of Mitotane caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [12]
Nilotinib DM7HXWT Major Increased metabolism of Mitotane caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [92]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Mitotane caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [93]
Dasatinib DMJV2EK Major Increased metabolism of Mitotane caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [26]
Vorapaxar DMA16BR Major Increased metabolism of Mitotane caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [94]
Modafinil DMYILBE Moderate Increased metabolism of Mitotane caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [95]
Rolapitant DM8XP26 Major Increased metabolism of Mitotane caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [12]
Netupitant DMEKAYI Major Increased metabolism of Mitotane caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [26]
Entrectinib DMMPTLH Major Increased metabolism of Mitotane caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [96]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Mitotane caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [97]
S-297995 DM26IH8 Major Increased metabolism of Mitotane caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [98]
Olaparib DM8QB1D Major Increased metabolism of Mitotane caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [26]
Rucaparib DM9PVX8 Moderate Increased metabolism of Mitotane caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [99]
Buprenorphine DMPRI8G Moderate Increased metabolism of Mitotane caused by Buprenorphine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [100]
Hydrocodone DMQ2JO5 Major Increased metabolism of Mitotane caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [45]
Istradefylline DM20VSK Major Increased metabolism of Mitotane caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [101]
Pimavanserin DMR7IVC Moderate Increased metabolism of Mitotane caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [102]
Macimorelin DMQYJIR Moderate Increased metabolism of Mitotane caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [103]
Lefamulin DME6G97 Major Increased metabolism of Mitotane caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [104]
Ergonovine DM0VEC1 Moderate Increased metabolism of Mitotane caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [26]
Lonafarnib DMGM2Z6 Major Increased metabolism of Mitotane caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [105]
ABIRATERONE DM8V75C Major Increased metabolism of Mitotane caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [106]
Enzalutamide DMGL19D Moderate Increased metabolism of Mitotane caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [107]
Darolutamide DMV7YFT Moderate Increased metabolism of Mitotane caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [108]
Silodosin DMJSBT6 Moderate Increased metabolism of Mitotane caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [26]
Apremilast DMTWS9E Major Increased metabolism of Mitotane caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [109]
Riociguat DMXBLMP Moderate Increased metabolism of Mitotane caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [110]
Everolimus DM8X2EH Major Increased metabolism of Mitotane caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [45]
Axitinib DMGVH6N Major Increased metabolism of Mitotane caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [111]
Temsirolimus DMS104F Major Increased metabolism of Mitotane caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [26]
Upadacitinib DM32B5U Major Increased metabolism of Mitotane caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [112]
Tofacitinib DMBS370 Major Increased metabolism of Mitotane caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [26]
Quetiapine DM1N62C Major Increased metabolism of Mitotane caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [26]
Aripiprazole DM3NUMH Moderate Increased metabolism of Mitotane caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [113]
Avanafil DM75CXN Moderate Increased metabolism of Mitotane caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [114]
Tadalafil DMJZHT1 Moderate Increased metabolism of Mitotane caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [12]
Voxelotor DMCS6M5 Major Increased metabolism of Mitotane caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [115]
LDE225 DMM9F25 Major Increased metabolism of Mitotane caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [116]
Larotrectinib DM26CQR Major Increased metabolism of Mitotane caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Docetaxel DMDI269 Moderate Increased metabolism of Mitotane caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [117]
Trabectedin DMG3Y89 Major Increased metabolism of Mitotane caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
Armodafinil DMGB035 Moderate Increased metabolism of Mitotane caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [95]
Vandetanib DMRICNP Moderate Increased metabolism of Mitotane caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [118]
Norethindrone DMTY169 Moderate Increased metabolism of Mitotane caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [50]
Taxol DMUOT9V Moderate Increased metabolism of Mitotane caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [119]
Doxorubicin DMVP5YE Moderate Increased metabolism of Mitotane caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
Pitolisant DM8RFNJ Major Increased metabolism of Mitotane caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [12]
Warfarin DMJYCVW Moderate Increased metabolism of Mitotane caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [39]
Pomalidomide DMTGBAX Moderate Increased metabolism of Mitotane caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [120]
Fostamatinib DM6AUHV Major Increased metabolism of Mitotane caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [121]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Mitotane due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [99]
As-1670542 DMV05SW Moderate Increased metabolism of Mitotane caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [12]
Apixaban DM89JLN Moderate Increased metabolism of Mitotane caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [122]
Brilinta DMBR01X Major Increased metabolism of Mitotane caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [123]
Cabozantinib DMIYDT4 Major Increased metabolism of Mitotane caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [124]
Sirolimus DMGW1ID Major Increased metabolism of Mitotane caused by Sirolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [26]
Tacrolimus DMZ7XNQ Major Increased metabolism of Mitotane caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [125]
Saxagliptin DMGXENV Moderate Increased metabolism of Mitotane caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [126]
Linagliptin DMWFJTR Moderate Increased metabolism of Mitotane caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [127]
Elagolix DMB2C0E Moderate Increased metabolism of Mitotane caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [128]
Amiodarone DMUTEX3 Major Increased metabolism of Mitotane caused by Amiodarone mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [129]
⏷ Show the Full List of 185 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mitotane 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6957).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94.
4 Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study. Pharmacogenomics. 2012 Sep;13(12):1351-61. doi: 10.2217/pgs.12.116.
5 Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):281-9.
6 Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors. Anal Bioanal Chem. 2004 Feb;378(3):664-9. doi: 10.1007/s00216-003-2251-0. Epub 2003 Oct 25.
7 Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
8 The effect of mitotane on viability, steroidogenesis and gene expression in NCI295R adrenocortical cells. Mol Med Rep. 2013 Mar;7(3):893-900.
9 Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicology. 2012 Aug 16;298(1-3):14-23.
10 Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab. 2006 Jun;91(6):2165-70. doi: 10.1210/jc.2005-2157. Epub 2006 Mar 21.
11 The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells. Environ Health Perspect. 2012 Sep;120(9):1291-6. doi: 10.1289/ehp.1104296. Epub 2012 May 18.
12 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
14 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
16 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
17 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
18 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
19 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
20 Product Information. Lysodren (mitotane). Bristol-Myers Squibb, Princeton, NJ.
21 Nassr N, Huennemeyer A, Herzog R, et al. "Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects." Br J Clin Pharmacol 68 (2009): 580-7. [PMID: 19843061]
22 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
23 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
24 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
26 Cerner Multum, Inc. "Australian Product Information.".
27 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
28 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
29 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
30 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
31 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
32 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
33 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
34 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
36 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
37 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
39 Cuddy PG, Loftus LS "Influence of mitotane on the hypoprothrombinemic effect of warfarin." South Med J 79 (1986): 387-8. [PMID: 3952554]
40 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
41 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
42 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
43 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
44 Kharasch ED, Thummel KE "Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?" Anesth Analg 76 (1993): 1033-9. [PMID: 8484504]
45 Canadian Pharmacists Association.
46 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
47 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
48 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
49 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
50 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
51 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
52 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
53 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
54 Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH "Pharmacokinetic interactions with felbamate.In vitro-in vivo correlation." Clin Pharmacokinet 33 (1997): 214-24. [PMID: 9314612]
55 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
56 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
57 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
58 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
59 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
60 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
61 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
62 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
63 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
64 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
65 Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA "Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients." Antiviral Res 35 (1997): 53-63. [PMID: 9224961]
66 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
67 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
68 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
69 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
70 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
71 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
72 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
73 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
74 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
75 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
76 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
77 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
78 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
79 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
80 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
81 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
83 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
84 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
85 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
86 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
87 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
88 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
89 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
90 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
91 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
92 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
93 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
94 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
95 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
96 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
97 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
98 Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
99 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
100 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
101 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
102 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
103 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
104 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
105 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
106 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
107 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
108 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
109 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
110 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
111 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
112 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
113 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
114 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
115 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
116 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
117 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
118 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
119 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
120 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
121 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
122 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
123 Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
124 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
125 Bhaloo S, Prasad GV "Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report." Transplant Proc 35 (2003): 2449-51. [PMID: 14611983]
126 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
127 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
128 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
129 Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.